日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

伊沙妥昔单抗单药治疗用于高度致敏的肾移植等待患者的脱敏治疗

Vincenti, Flavio; Bestard, Oriol; Brar, Amarpali; Cruzado, Josep M; Seron, Daniel; Gaber, A Osama; Ali, Nicole; Tambur, Anat R; Lee, Helen; Abbadessa, Giovanni; Paul, Jo-Anne; Dudek, Markus; Siegel, Ruby J; Torija, Alba; Semiond, Dorothée; Lépine, Lucie; Ternes, Nils; Montgomery, Robert A; Stegall, Mark

A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

一项多中心 Ib 期研究,评估皮下注射伊沙妥昔单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤患者的疗效。

Quach, Hang; Parmar, Gurdeep; Ocio, Enrique M; Prince, H Miles; Oriol, Albert; Crowther, Helen; Tsukada, Nobuhiro; Bories, Pierre; Madan, Sumit; Nathwani, Nitya; Sunami, Kazutaka; Semiond, Dorothee; Yu, Disa; Cordero, Paul; Macé, Sandrine; Suzan, Florence; Moreau, Philippe

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

伊沙妥昔单抗单药治疗中国复发/难治性多发性骨髓瘤患者的I期研究

Sun, Mingyuan; Jing, Hongmei; Qu, Xiaoyan; Dong, Fei; Li, Yi; Feng, Zhaoyi; Ziti-Ljajic, Samira; Semiond, Dorothee; Li, Lingyu; Qi, Junyuan; Qiu, Lugui

Isatuximab-dexamethasone-pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data

伊沙妥昔单抗-地塞米松-泊马度胺联合用药对多发性骨髓瘤患者血清M蛋白和无进展生存期的影响:基于I/II期数据的联合模型构建

Pitoy, Antoine; Desmée, Solène; Riglet, François; Thai, Hoai-Thu; Klippel, Zandra; Semiond, Dorothée; Veyrat-Follet, Christine; Bertrand, Julie

Model-based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

基于模型的模拟研究旨在支持批准伊沙妥昔单抗单药或联合地塞米松用于治疗日本复发/难治性多发性骨髓瘤患者。

Thai, Hoai-Thu; Koiwai, Kimiko; Shitara, Yoshihisa; Kazama, Hirotaka; Fau, Jean-Baptiste; Semiond, Dorothée; Veyrat-Follet, Christine

Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

在多发性骨髓瘤患者中,通过暴露-反应分析选择/确认伊沙妥昔单抗联合泊马度胺/地塞米松治疗的最佳给药方案

Rachedi, Fatiha; Koiwai, Kimiko; Gaudel-Dedieu, Nadia; Sebastien, Bernard; Thai, Hoai-Thu; Brillac, Claire; Fau, Jean Baptiste; Nguyen, Laurent; van de Velde, Helgi; Veyrat-Follet, Christine; Semiond, Dorothée

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

一项针对达雷妥尤单抗耐药的多发性骨髓瘤患者的伊沙妥昔单抗单药治疗的 II 期研究

Mikhael, Joseph; Belhadj-Merzoug, Karim; Hulin, Cyrille; Vincent, Laure; Moreau, Philippe; Gasparetto, Cristina; Pour, Ludek; Spicka, Ivan; Vij, Ravi; Zonder, Jeffrey; Atanackovic, Djordje; Gabrail, Nashat; Martin, Thomas G; Perrot, Aurore; Bensfia, Samira; Weng, Qilong; Brillac, Claire; Semiond, Dorothée; Macé, Sandrine; Corzo, Kathryn P; Leleu, Xavier

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

对伊沙妥昔单抗单药及联合治疗多发性骨髓瘤患者进行PK/PD模型分析,以确定给药方案。

Koiwai, Kimiko; El-Cheikh, Raouf; Thai, Hoai-Thu; Brillac, Claire; Fau, Jean-Baptiste; Veyrat-Follet, Christine; Risse, Marie-Laure; van de Velde, Helgi; Semiond, Dorothée; Nguyen, Laurent

Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

伊沙妥昔单抗在复发/难治性多发性骨髓瘤患者中的药物-疾病相互作用和时间依赖性群体药代动力学

Fau, Jean-Baptiste; El-Cheikh, Raouf; Brillac, Claire; Koiwai, Kimiko; Mace, Nathalie; Campana, Frank; Semiond, Dorothee; Nguyen, Laurent

Preclinical profile of cabazitaxel

卡巴他赛的临床前特征

Vrignaud, Patricia; Semiond, Dorothée; Benning, Veronique; Beys, Eric; Bouchard, Hervé; Gupta, Sunil